Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP5 | P51878 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22892136 | 1.00 | CHRM5 (0.59) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL15251335 | 0.90 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL20663187 | 0.88 | CHRM5 (0.58) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL10945980 | 0.88 | CHRM5 (0.52) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL18407087 | 0.85 | ACHE (0.48) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL3611455 | 0.80 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL1564103 | 0.80 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL27097596 | 0.80 | ACHE (0.62) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL27097437 | 0.80 | ACHE (0.62) | CHRM5ADRA2CACHESMN1; SMN2HRH3 | |
| SCHEMBL12716928 | 0.79 | CHRM5 (0.58) | CHRM5ADRA2CACHESMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | CHRM5 3562/4885ADRA2C 2546/4885ACHE 3678/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | CHRM5 3562/4885ADRA2C 2546/4885ACHE 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.